Neurogene (NASDAQ:NGNE) Earns Outperform Rating from Analysts at Lifesci Capital

Lifesci Capital initiated coverage on shares of Neurogene (NASDAQ:NGNE) in a research report released on Monday morning, MarketBeat.com reports. The brokerage issued an outperform rating and a $50.00 price objective on the stock. Lifesci Capital also issued estimates for Neurogene’s Q4 2025 earnings at ($1.17) EPS, FY2025 earnings at ($4.26) EPS, Q1 2026 earnings at ($1.19) EPS, Q2 2026 earnings at ($1.21) EPS, Q3 2026 earnings at ($0.99) EPS, Q4 2026 earnings at ($1.00) EPS, FY2026 earnings at ($4.33) EPS, FY2027 earnings at ($3.96) EPS, FY2028 earnings at ($0.63) EPS, FY2029 earnings at $5.80 EPS and FY2030 earnings at $12.83 EPS.

Several other brokerages have also recently issued reports on NGNE. Weiss Ratings reiterated a “sell (d-)” rating on shares of Neurogene in a research note on Thursday, January 22nd. Wall Street Zen downgraded shares of Neurogene from a “hold” rating to a “sell” rating in a research note on Saturday, December 13th. Finally, HC Wainwright reissued a “buy” rating and issued a $70.00 price objective on shares of Neurogene in a research report on Tuesday, January 13th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $44.00.

Neurogene Stock Down 3.0%

Shares of NGNE stock opened at $19.27 on Monday. The firm has a 50 day moving average of $19.65 and a two-hundred day moving average of $21.99. The stock has a market capitalization of $298.49 million, a PE ratio of -4.69 and a beta of 1.60. Neurogene has a 52 week low of $6.88 and a 52 week high of $37.27.

Neurogene (NASDAQ:NGNE) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.99) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.26) by $0.27. Analysts expect that Neurogene will post -4.27 EPS for the current fiscal year.

Institutional Investors Weigh In On Neurogene

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets boosted its stake in Neurogene by 89.8% in the third quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company’s stock valued at $36,000 after acquiring an additional 978 shares in the last quarter. PNC Financial Services Group Inc. boosted its position in shares of Neurogene by 43.6% in the 2nd quarter. PNC Financial Services Group Inc. now owns 4,055 shares of the company’s stock valued at $61,000 after purchasing an additional 1,232 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Neurogene by 17.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock worth $82,000 after buying an additional 1,059 shares during the last quarter. Bridgeway Capital Management LLC acquired a new position in Neurogene during the third quarter worth approximately $187,000. Finally, Brevan Howard Capital Management LP purchased a new stake in Neurogene in the third quarter valued at approximately $223,000. 52.37% of the stock is currently owned by institutional investors and hedge funds.

Neurogene News Roundup

Here are the key news stories impacting Neurogene this week:

• Positive Sentiment: LifeSci Capital initiated coverage with an “Outperform” rating and a $50 price target, which supports upside sentiment and gives investors a clear bull-case reference point. Lifesci Capital Begins Coverage on Neurogene
• Neutral Sentiment: LifeSci published a detailed multi-year forecast: deep losses through FY2026–FY2028 but large earnings in FY2029 ($5.80 EPS) and FY2030 ($12.83 EPS). The long horizon to profitability means the price target rests on successful execution and late-stage commercialization assumptions.
• Negative Sentiment: Near-term estimates are materially negative: quarterly EPS forecasts ~($1.00) and full-year FY2026 EPS around ($4.33). Those continued losses and clinical/operational risk likely keep selling pressure despite the initiation.
• Neutral Sentiment: The analyst view diverges from the current consensus (consensus full-year EPS ~($4.27)), so the initiation may gradually influence estimates, but any immediate re-rating depends on program milestones and cash/burn visibility.

Neurogene Company Profile

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.